AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 146 min read

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics reported Phase 3 REZILIENT3 trial results, showing zipalertinib plus chemotherapy improved progression-free survival in EGFR exon 20 insertion mutation NSCLC patients. Median PFS increased by 6.0 months (HR=0.50). The companies view zipalertinib as a key growth driver, though earnings forecasts remain unchanged.

Original reporting
marketscreener.com
Published Sep 14, 2026, 8:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$CGEM
Relevance
8/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The article reports the planned interim PFS analysis meeting the primary endpoint with a large effect size, while interim OS remains immature. Safety shows no new signals but higher grade 3 AEs, mainly manageable hematologic events.

02

Market read

Pivotal interim PFS success with strong ORR and no new safety signals is a material catalyst for the zipalertinib program, but the lack of OS confirmation and higher grade 3 AE rate may temper immediate valuation impact.

03

What to watch

Open-label design and interim analysis timing can overstate durability; investors may also focus on how hematologic toxicity is managed and whether the OS signal strengthens with more event maturity.

Relevance 8/10Novelty 8/10Timing: pre-market today (published 2026-09-14 08:05:51 UTC)

Background

REZILIENT3 is a Phase 3 randomized trial in previously untreated advanced/metastatic EGFR exon 20 insertion NSCLC, comparing zipalertinib plus platinum-based chemotherapy versus chemotherapy alone.

Market effects

Sector

Reinforces competitive momentum in EGFR exon 20 insertion targeted therapies, potentially raising the bar for efficacy and tolerability in this subgroup.

Regional

Could spill over to global biotech sentiment, especially in oncology-focused names with EGFR ex20ins programs.

Global

IASLC WCLC presentation selection may amplify attention from international oncology investors and analysts ahead of further OS updates.

Counterpoint

What could challenge this read

Interim OS is not statistically conclusive (HR 0.72 with CI spanning 1), and grade 3 AEs are substantially higher, which could limit enthusiasm until longer follow-up and tolerability data are clearer.

Key entities

  • clinical_trial
    REZILIENT3

    Phase 3 trial of zipalertinib plus chemotherapy versus chemotherapy alone in first-line EGFR ex20ins NSCLC.

  • investigational_drug
    zipalertinib

    Orally available irreversible EGFR inhibitor targeting EGFR exon 20 insertion mutations; investigational and not approved.

  • trial_registry
    ClinicalTrials.gov NCT05973773

    Registry identifier for REZILIENT3.

  • conference
    IASLC 2026 WCLC Presidential Symposium 2

    Planned presentation venue for the late-breaking interim results.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 14
$CGEMMedAI 8/10

Cullinan Therapeutics stock falls despite positive trial data

Cullinan Therapeutics (CGEM) shares fell 6.3% despite positive Phase 3 trial results for zipalertinib in lung cancer treatment. The REZILIENT3 trial met its primary endpoint, showing a 6.0-month improvement in median progression-free survival compared to chemotherapy alone. The company plans to discuss the results with health authorities. According to Cullinan, the trial enrolled 279 patients with advanced NSCLC.

investing.com2 min
SEP 14
$CGEMHighAI 8/10

Cullinan Therapeutics: Zipalertinib + chemo cuts median PFS to 14.5 vs 8.5 months in REZILIENT3

Cullinan Therapeutics reported that its drug zipalertinib, combined with chemotherapy, showed a median progression-free survival of 14.5 months compared to 8.5 months with chemotherapy alone in the Phase 3 REZILIENT3 trial. The study included 279 patients with EGFR ex20ins NSCLC. The combination also achieved a higher objective response rate (65.0% vs. 40.3%) and longer median duration of response (14.2 vs. 9.9 months). Safety data showed higher Grade ≥3 adverse events with the combination, prim

tradingview.com1 min
SEP 13
$CGEMMedAI 8/10

Zipalertinib plus chemo shows survival benefit in lung cancer trial

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib plus chemotherapy in lung cancer. The combination improved progression-free survival by 6.0 months (14.5 vs. 8.5 months) with a hazard ratio of 0.50. The trial enrolled 279 patients, with objective response rates of 65.0% for the combination vs. 40.3% for chemotherapy alone. Zipalertinib is not yet approved.

investing.com2 min
SEP 13
$CGEMHighAI 8/10

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced positive Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC. The combination showed a 6.0-month median PFS improvement (HR=0.50, P=0.00015) and higher response rates. Data were presented at WCLC 2026. The companies plan to discuss results with health authorities.

finance.yahoo.com3 min